[HTML][HTML] Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives
LA Godoy, J Chen, W Ma, J Lally, KA Toomey… - Biomarker …, 2023 - Springer
Over the past decade, targeted therapy for oncogene-driven NSCLC and immune
checkpoint inhibitors for non-oncogene-driven NSCLC, respectively, have greatly improved …
checkpoint inhibitors for non-oncogene-driven NSCLC, respectively, have greatly improved …
Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives.
LA Godoy, J Chen, W Ma, J Lally, KA Toomey… - Biomarker …, 2023 - europepmc.org
Over the past decade, targeted therapy for oncogene-driven NSCLC and immune
checkpoint inhibitors for non-oncogene-driven NSCLC, respectively, have greatly improved …
checkpoint inhibitors for non-oncogene-driven NSCLC, respectively, have greatly improved …
Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives.
L Godoy, J Chen, W Ma, J Lally, K Toomey… - Biomarker …, 2023 - escholarship.org
Over the past decade, targeted therapy for oncogene-driven NSCLC and immune
checkpoint inhibitors for non-oncogene-driven NSCLC, respectively, have greatly improved …
checkpoint inhibitors for non-oncogene-driven NSCLC, respectively, have greatly improved …
[HTML][HTML] Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives
LA Godoy, J Chen, W Ma, J Lally… - Biomarker …, 2023 - biomarkerres.biomedcentral.com
Over the past decade, targeted therapy for oncogene-driven NSCLC and immune
checkpoint inhibitors for non-oncogene-driven NSCLC, respectively, have greatly improved …
checkpoint inhibitors for non-oncogene-driven NSCLC, respectively, have greatly improved …
[HTML][HTML] Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives
LA Godoy, J Chen, W Ma, J Lally, KA Toomey… - Biomarker …, 2023 - ncbi.nlm.nih.gov
Over the past decade, targeted therapy for oncogene-driven NSCLC and immune
checkpoint inhibitors for non-oncogene-driven NSCLC, respectively, have greatly improved …
checkpoint inhibitors for non-oncogene-driven NSCLC, respectively, have greatly improved …
Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives.
LA Godoy, J Chen, W Ma, J Lally… - Biomarker …, 2023 - search.ebscohost.com
Over the past decade, targeted therapy for oncogene-driven NSCLC and immune
checkpoint inhibitors for non-oncogene-driven NSCLC, respectively, have greatly improved …
checkpoint inhibitors for non-oncogene-driven NSCLC, respectively, have greatly improved …
Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives
LA Godoy, J Chen, W Ma, J Lally… - Biomarker …, 2023 - pubmed.ncbi.nlm.nih.gov
Over the past decade, targeted therapy for oncogene-driven NSCLC and immune
checkpoint inhibitors for non-oncogene-driven NSCLC, respectively, have greatly improved …
checkpoint inhibitors for non-oncogene-driven NSCLC, respectively, have greatly improved …
[引用][C] Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives
LA Godoy, J Chen, W Ma, J Lally, KA Toomey… - europepmc.org
Over the past decade, targeted therapy for oncogene-driven NSCLC and immune
checkpoint inhibitors for nononcogene-driven NSCLC, respectively, have greatly improved …
checkpoint inhibitors for nononcogene-driven NSCLC, respectively, have greatly improved …
[PDF][PDF] Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives
LA Godoy, J Chen, W Ma, J Lally, KA Toomey… - biomarkerres.biomedcentral.com
Over the past decade, targeted therapy for oncogene-driven NSCLC and immune
checkpoint inhibitors for nononcogene-driven NSCLC, respectively, have greatly improved …
checkpoint inhibitors for nononcogene-driven NSCLC, respectively, have greatly improved …